- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Anonymous complaint about a Madrid meeting: a pre-meeting “gala dinner” created a lavish impression and was ruled not secondary to the meeting’s…
Complaint about a Praluent advertorial on the HSJ website alleged it was unsuitable for public access and links/references were problematic. The PMCPA…
Anonymous complaint about a Shire meeting advertised on LinkedIn. PMCPA concluded no breach because the matter was outwith the scope of the…
A MIMS print ad for Strivit-D3 used ‘The Licensed Vitamin D3 of Choice’. PMCPA ruled it implied first-choice status and was misleading/exaggerated…
Guidelines in Practice-hosted Ranexa case study wasn’t disguised online, but the downloadable PDF didn’t clearly show Menarini involvement on the front page,…
An anonymous UK health professional complained Avamys’ generic name was unreadable in a Pulse website banner. PMCPA found breaches of Clauses 4.3…
PMCPA ruled Vifor’s Ferinject site landing page promoted a POM to the public (Clause 26.1) and an HCP claim that Ferinject was…
Employee alleged Jinarc EU risk minimisation materials omitted pregnancy/dehydration info and that Otsuka lacked urgency on patient safety. Panel and Appeal Board…
MSD promoted a diabetes/CVD meeting via a targeted LinkedIn sponsored post. A complainant said a patient saw it and couldn’t register. Panel…
Anonymous complaint about Boehringer Ingelheim’s Twitter/Facebook activity advertising a webinar. Panel found the Twitter ad and registration page were non-promotional and gated…
Novartis’ Beovu journal ad claimed it ‘outperformed aflibercept’ on retinal fluid resolution. PMCPA ruled the headline misleading: it overplayed a secondary/exploratory endpoint…
Anonymous GP alleged a Pfizer rep disparaged Xarelto and claimed Eliquis’ superior safety should be used to address mortality in primary care.…
A subcontracted agency posted Oxlumo brand/indication details on LinkedIn. PMCPA ruled promotion of a POM to the public (Clause 26.1 breach). No…
PMCPA found breaches for GSK respiratory materials: meeting invitations omitted non-proprietary names/black triangles/AE statement, one invite implied Trelegy was licensed for asthma,…
A senior UK employee ‘liked’ a global LinkedIn post naming tildrakizumab/Ilumetri and 5-year efficacy/safety. Panel found this proactively disseminated promotion (incl to…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.